Skip to main content

GIL

Stock
Consumer Discretionary
Apparel Manufacturing

Performance overview

GIL Price
Price Chart

Forward-looking statistics

Beta
0.58
Risk
22.15%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Gildan is a vertically integrated designer and manufacturer of basic apparel, including T-shirts, underwear, socks, and hosiery. Its primary market is the sale of blank T-shirts, sweatshirts, and other apparel to wholesalers, major clothing brands, and printers (printwear). Gildan also sells branded clothing through retail and direct-to-consumer channels. Brands include Gildan, American Apparel, Comfort Colors, and Gold Toe. Gildan produces most of its clothing at factories in Latin America and recently began operating a new plant in Bangladesh. Incorporated in 1984, the Montreal-based company operates internationally but generates nearly 90% of its sales in the US.

Company info

SectorConsumer Discretionary
IndustryApparel Manufacturing
Employees24K
Market cap$6.5B

Fundamentals

Enterprise value$9.2B
Revenue$3.3B
Revenue per employee
Profit margin12.38%
Debt to equity137.32

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$2.55
Dividend per share$0.90
Revenue per share$20.71
Avg trading volume (30 day)$29M
Avg trading volume (10 day)$23M
Put-call ratio

Macro factor sensitivity

Growth+0.3
Credit+4.6
Liquidity-0.3
Inflation-1.6
Commodities-0.5
Interest Rates-3.0

Valuation

Dividend yield1.78%
PEG Ratio10.57
Price to sales2.34
P/E Ratio10.57
Enterprise Value to Revenue2.81
Price to book5.48

Upcoming events

Next earnings dayApril 30, 2025
Next dividend day
Ex. dividend dayMay 20, 2025

News

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research (July 10, 2025)
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead's twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Benzinga (July 9, 2025)
Final Trades: Synovus, Nextera Energy, Gilead and the IYF

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television (July 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free